Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJingbo Yu

Discussion

Loading...

Member takes

Overview

Real-world analysis shows Ruxolitinib reduces phlebotomy use in polycythemia vera patients, indicating clinical benefits over 4 years.

Key Points

  • Median Ruxolitinib treatment duration for polycythemia vera was 42 months, with over one-third still on treatment by study's end.
  • Among those needing phlebotomy initially, 60% were phlebotomy-free within 6 months of starting Ruxolitinib.
  • Retrospective analysis used Medicare claims data to assess treatment effects in 2369 patients regarding phlebotomy.
  • Sustained long-term use supports Ruxolitinib’s effectiveness as a treatment option for polycythemia vera.

Cite This Study

Jingbo Yu (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7f7https://doi.org/10.1182/blood-2025-2826
View Full Paper
Ask AI
Bookmark
Share